

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Cancer	Macrophage stimulating 1 receptor c-Met-related tyrosine kinase (MST1R; RON; CD136); c-Met proto-oncogene (MET; HGFR)	<p>Mouse studies suggest inhibiting RON could help treat metastatic cancers by inducing an antitumor immune response. In an immune-competent mouse model for metastatic breast cancer, knockout of <i>Mst1r</i> eliminated metastasis and induced a more robust CD8<sup>+</sup> T cell antitumor response than no knockout. ASLAN002, an inhibitor of MET and RON, decreased metastasis to the lungs of mice compared with vehicle. Next steps include combination studies with chemotherapy.</p> <p>Aslan Pharmaceuticals Pte. Ltd.'s ASLAN002 (formerly BMS-777607) is in Phase I trials to treat cancer.</p> <p>Eli Lilly and Co.'s narnatumab (IMC-RON8), an anti-RON mAb, is in Phase I testing to treat cancer.</p> <p><b>SciBX 6(21); doi:10.1038/scibx.2013.514</b>  <b>Published online May 30, 2013</b></p>	Unpatented; licensing status not applicable	<p>Eyob, H. <i>et al. Cancer Discov.</i>; published online April 23, 2013; doi:10.1158/2159-8290.CD-12-0480</p> <p><b>Contact:</b> Alana L. Welm, Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah  e-mail: <a href="mailto:alana.welm@hci.utah.edu">alana.welm@hci.utah.edu</a></p>